Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | THRB | P10828 | 3/20 | 0.58 |
| ▸ | F10 | P00742 | 4/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7234016 | 0.89 | MAPT (0.55) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL6599256 | 0.87 | MAPT (0.53) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL6599254 | 0.87 | MAPT (0.56) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL6596058 | 0.87 | MAPT (0.53) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL6596946 | 0.86 | MAPT (0.59) | MAPTTHRBF10ALDH1A1GAA | |
| SCHEMBL6433700 | 0.85 | CCR2 (0.54) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL6595855 | 0.84 | MAPT (0.49) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL6308907 | 0.81 | MAPT (0.59) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL3963296 | 0.81 | CCR2 (0.72) | CCR2MTNR1AMTNR1BMAPTTHRB | |
| SCHEMBL7884326 | 0.80 | KMT2A (0.72) | CCR2MTNR1AMTNR1BMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0950661-B1 | Substituted tricyclics useful in sPLA2 induced diseases | LILLY CO ELI (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1156050-A2 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0950661-A1 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |